Please assess the completion status of the following clinical trial:

Trial Title: HALT Progression of Polycystic Kidney Disease Study A

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of ADPKD.~* Age 15-49 (Study A); Age 18-64 (Study B).~* GFR \>60 mL/min/1.73 m2 (Study A); GFR 25-60 mL/min/1.73 m2 (Study B).~* BP ≥130/80 or receiving treatment for hypertension.~* Informed Consent.~Exclusion Criteria:~* Pregnant/intention to become pregnant in 4-6 yrs.~* Documented renal vascular disease.~* Spot urine albumin-to-creatinine ratio of \>0.5 (Study A) or ≥1.0 (Study B) and/or findings suggestive of kidney disease other than ADPKD.~* Diabetes requiring insulin or oral hypoglycemic agents / fasting serum glucose of \>126 mg/dl / random non-fasting glucose of \>200 mg/dl.~* Serum potassium \>5.5 milliequivalent per liter (mEq/L) for participants currently on ACE-I or ARB; \>5.0 mEq/L for participants not currently on ACE-I or ARB.~* History of angioneurotic edema or other absolute contraindication for ACE-I or ARB. Intolerable cough associated with ACE-I is defined as a cough developing within six months of initiation of ACE-I in the absence of other causes and resolving upon discontinuation of the ACE-I.~* Indication (other than hypertension) for β-blocker or calcium channel blocker therapy (e.g. angina, past myocardial infarction, arrhythmia), unless approved by the site principal investigator. (PI may choose to accept an individual who is on only a small dose of one of these agents and would otherwise be eligible.)~* Systemic illness necessitating nonsteroidal antiinflammatory drugs (NSAIDs), immunosuppressant or immunomodulatory medications.~* Systemic illness with renal involvement.~* Hospitalized for acute illness in past 2 months.~* Life expectancy \<2 years.~* History of non-compliance.~* Unclipped cerebral aneurysm \>7mm diameter.~* Creatine supplements within 3 months of screening visit.~* Congenital absence of a kidney (also total nephrectomy for Study B).~* Known allergy to sorbitol or sodium polystyrene sulfonate.~* Exclusions specific to magnetic resonance imaging (Study A).

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Study A, Arm 1 (Type: ACTIVE_COMPARATOR): Lisinopril + Telmisartan (ACE-I + ARB) and standard blood pressure control of 120-130/70-80 mm Hg
- Study A, Arm 2 (Type: ACTIVE_COMPARATOR): Lisinopril + Telmisartan (ACE-I + ARB) and low blood pressure control of 95-110/60-75 mm Hg
- Study A, Arm 3 (Type: PLACEBO_COMPARATOR): Lisinopril + Placebo (ACE-I + Placebo) and standard blood pressure control of 120-130/70-80 mm Hg
- Study A, Arm 4 (Type: PLACEBO_COMPARATOR): Lisinopril + Placebo (ACE-I + Placebo) and low blood pressure control of 95-110/60-75 mm Hg

Based on this trial design, predict the completion outcome and termination type (if applicable).